Evidence map›Paper›PMID 21646400›Full record

ReviewThe Journal of experimental medicine2011

New ways to turn on NKT cells.

Dale Ian Godfrey, Jamie Rossjohn

Open access · bronzeAbstract readReview
In one paragraph

Review in The Journal of experimental medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 84 citations in OpenAlex.

  1. Trial
  2. Review
  3. CD1d-Restricted NKT Cells Promote Central Memory CD8International journal of molecular sciences · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. NKT cells in liver diseases.Frontiers of medicine · 2018
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Bee venom processes human skin lipids for presentation by CD1a.The Journal of experimental medicine · 2015
    Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Dale Ian GodfreyDept. of Microbiology and Immunology, University of Melbourne, Parkville, Victoria 3010, Australia. godfrey@unimelb.edu.au
Jamie Rossjohn
Monash University · AUUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer T (NKT) cells are CD1d-restricted, lipid antigen-reactive T cells with powerful immunoregulatory potential. The prototypic antigen for NKT cells is a marine sponge-derived glycolipid, α-galactosylceramide (α-GalCer), but this is not normally encountered in the mammalian environment. Thus, there is great interest in the identification of more physiological stimuli for NKT cells, and numerous studies have shown that NKT cells are capable of responding to a range of microbial lipid-based antigens. Two new studies expand our understanding of environmental NKT cell stimuli, with one showing that CD1d-restricted NKT cell antigens are present within common house dust extract (HDE), whereas the other shows that NKT cells can respond to innate stimuli irrespective of the presence of foreign microbial antigens. Collectively, these two investigations indicate that NKT cells are far more likely to encounter foreign antigens, or innate activating signals, than previously recognized, suggesting a more central role for these cells in the immune system.

Indexed as

AnimalsAntigens, CD1dCytokinesGalactosylceramidesGlycolipidsHumansImmune SystemInflammationLipidsLymphocyte ActivationMiceModels, BiologicalNatural Killer T-Cellsalpha-galactosylceramideAntigens, CD1dCytokinesGalactosylceramidesGlycolipidsLipids

Identifiers

PMID21646400
PMCPMC3173239
OpenAlexW2159511210

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.